Table 1.
Patient, tumor and treatment characteristics.
| Variable | Median (range) |
|---|---|
| Age (years) | 56.0 (27–81) |
| Overall follow-up (months)a | 55.8 (8.1–95.5) |
| Variable | n (column percent) |
|
| |
| Sex | |
| Male | 86 (86.0%) |
| Female | 14 (14.0%) |
| Tumor site | |
| Tonsil | 42 (42.0%) |
| Base of tongue | 53 (53.0%) |
| Other | 5 (5.0%) |
| Tumor Stage | |
| T1 | 14 (14.0%) |
| T2 | 39 (39.0%) |
| T3 | 23 (23.0%) |
| T4 | 24 (24.0%) |
| Nodal Stage | |
| N0 | 4 (4.0%) |
| N1 | 12 (12.0%) |
| N2 | 80 (80.0%) |
| N3 | 4 (4.0%) |
| KPSb | |
| 100–90 | 79 (84.9%) |
| ≤80 | 14 (15.1%) |
| Smoking history | |
| No | 28 (28.0%) |
| Yes | 72 (72.0%) |
| Chemotherapy regimen | |
| Cisplatin alone | 61 (61.0%) |
| Cisplatin + bevacizumab | 16 (16.0%) |
| Cisplatin + paclitaxel | 1 (1/0%) |
| Carboplatinum + 5-fluorouracil | 19 (19.0%) |
| Carboplatinum + paclitaxel | 3 (3.0%) |
Abbreviation: KPS, Karnofsky Performance Status.
a
Among living patients.
b
N=93 patients.